Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10141027 | 1.00 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP3A4L3MBTL1GAA | |
| SCHEMBL754074 | 0.85 | LMNA (0.38) | CYP1A2CYP2D6CYP3A4L3MBTL1MAPT | |
| SCHEMBL890117 | 0.85 | GAA (0.35) | CYP1A2CYP2D6CYP3A4L3MBTL1GAA | |
| SCHEMBL890065 | 0.85 | GAA (0.35) | CYP1A2CYP2D6CYP3A4L3MBTL1GAA | |
| SCHEMBL8907693 | 0.82 | MAPT (0.32) | L3MBTL1GAAMAPTHRH3 | |
| SCHEMBL8912048 | 0.82 | MAPT (0.32) | L3MBTL1GAAMAPTHRH3 | |
| SCHEMBL19578134 | 0.81 | CA2 (0.34) | CYP1A2CYP2D6CYP3A4L3MBTL1GAA | |
| SCHEMBL8906714 | 0.81 | GAA (0.33) | L3MBTL1GAAMAPTHRH3 | |
| SCHEMBL10150853 | 0.81 | GAA (0.33) | L3MBTL1GAAMAPTHRH3 | |
| SCHEMBL12175194 | 0.80 | CTSK (0.40) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2011127350-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011091417-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| WO-2011031904-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CYP1A2 205/4885CYP2D6 594/4885CYP3A4 204/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CYP1A2 390/4885CYP2D6 478/4885CYP3A4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.